MedPath

Evaluation of Dermatological safety of the investigational products by applying patch on the upper back of healthy human volunteers

Not Applicable
Completed
Registration Number
CTRI/2011/11/002113
Lead Sponsor
ICHIMARU PHARCOS CO Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
24
Inclusion Criteria

1)Subjects with skin type III to V.

2)Subjects willing to give a written informed consent.

3)Subjects willing to maintain the patch test in position for 24 hours

4)Subject has not participated in a similar investigation in the past two weeks.

5)Subjects willing to come for regular follow up.

6)Subjects ready to follow instructions during the study period.

Exclusion Criteria

1)Infection, allergy on the tested area

2)History of skin allergy antecedents or atopic subjects

3)History of hyper sensitivity to any component of the tested products

4)Athletes and subjects with history of excessive sweating

5)Cutaneous disease which may influence the study result

6)Chronic illness which may influence the cutaneous state.

7)Subjects on oral corticosteroid with dose >10mg/day

8)Subjects participating in any other cosmetic or therapeutic trial.

9)Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test.Timepoint: To evaluate the dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test on Day 1, Day 2 & Day 7 of post patch application.
Secondary Outcome Measures
NameTimeMethod
To gather safety information prior to a pilot study and/or larger study, in order to improve the latterâ??s quality and efficiency of the study design.Timepoint: Dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test on Day 1, Day 2 & Day 7 of post patch application.
© Copyright 2025. All Rights Reserved by MedPath